par Koessler, Thibaud;Alsina, Maria;Arnold, Dirk;Ben-Aharon, Irit;Collienne, Maike;Lutz, Manfred M.P.;Neuzillet, Cindy;Obermannova, Radka;Peeters, Michel 
;Sclafani, Francesco ;Smyth, Elizabeth;Valle, Juan J.W.;Wagner, Anna Dorothea;Wyrwicz, Lucian;Fontana, Elisa;Moehler, Markus
Référence ESMO Open, 7, 2, 100392
Publication Publié, 2022-04
;Sclafani, Francesco ;Smyth, Elizabeth;Valle, Juan J.W.;Wagner, Anna Dorothea;Wyrwicz, Lucian;Fontana, Elisa;Moehler, MarkusRéférence ESMO Open, 7, 2, 100392
Publication Publié, 2022-04
Article révisé par les pairs
| Résumé : | There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future. |
